Gottlieb at BIO: FDA developing processes around right-to-try law
FDA commissioner gives clues of agency's right-to-try strategy in Q&A session during chat with BIO President Jim Greenwood.
P4HD Partners respond to USA Today letter written by John J. Castellani & Jim Greenwood
On February 24, USA Today ran a letter to the editor written by PhRMA President John J. Castellani and Biotechnology Industry Organization President Jim Greenwood responding to an editorial that not only mischaracterized the relationships between physicians and biopharmaceutical and medical technology professionals, but also admonished them. An additional rebuttal by Dr. Thomas Stossel, Professor […]
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Senate passes JOBS bill, but will early stage biotech companies benefit?
The U.S. Senate has approved a bill that will make it easier for early stage companies to raise money by broadening the number of people that can invest in them and help companies file for initial public offerings. But will it mean more biotechnology startups will have the money to survive the multiyear journey to […]